RPGLIFERPG Life Sciences Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on RPGLIFE — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Profit growth: 17.0% YoY
- • ROE: 19.0%
- • ROCE: 20.3%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Supertrend: bullish
Bull case
- • Profit growth: 17.0% YoY
- • ROE: 19.0%
- • ROCE: 20.3%
- • Price vs SMA200: above
Bear case
- • MACD: bearish
- • Price vs EMA21: below
- • 1-month return: -8.7%
- • 1-month vs NIFTY: -5.8% relative
Key risks
- • MACD: bearish
- • Price vs EMA21: below
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹149.53). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.